Abstract
Stroke remains a major cause of human disability worldwide. Interventions and rehabilitation at the poststroke stage are critical for recovery. A single-blinded randomized controlled trial was conducted on 61 patients diagnosed with subacute stage of ischemic stroke. Ingestion of Nattospecs was tested as an adjuvant to support rehabilitation when combined with standard of care (SOC) treatment (electroacupuncture and Naatrapyl) (Trial group) and compared to SOC treatment alone (Control group). After 60 days, results showed that both Trial and Control groups achieved significant improvements in physical activities, blood pressure control, serum lipid panels, and quality of life. Nattospes as a food supplement has good supportive effects on treatment and rehabilitation after ischemic stroke by showing statistically significant improvement of stroke-related symptom in scores from modified Rankin, Orgogozo, and Barthel scales. In addition, Nattospes showed a good safety profile, with no adverse effects reported in both clinical and paraclinical parameters. This study indicated that Nattospes as nutraceutical supplement can be applied safely and effectively in the management of subacute stage ischemic stroke. The findings of the study may also encourage further extensive clinical trials to fully explore the prospect of Nattospes as a nutraceutical adjunct in the management of cardiovascular disease.
Highlights
IntroductionStroke is a significant cause of death and disability around the world, with a reported 6.5 million deaths, 113 million disability-adjusted life-years lost, and 10.3 million new cases of stroke globally as of 2013.1,2 According to the American Heart Association, around 87% of strokes are ischemic strokes, which occurs when a blood vessel carrying blood to the brain is blocked by a blood clot, with hypertension being the leading risk factor.[3]
Stroke is a significant cause of death and disability around the world, with a reported 6.5 million deaths, 113 million disability-adjusted life-years lost, and 10.3 million new cases of stroke globally as of 2013.1,2 According to the American Heart Association, around 87% of strokes are ischemic strokes, which occurs when a blood vessel carrying blood to the brain is blocked by a blood clot, with hypertension being the leading risk factor.[3]Current acute stroke interventions to reduce disability only reach a fraction of patients
In the United States, the only drug approved to treat an acute stroke is through an IV injection of tissue plasminogen activator,[4,5] which is limited in its effectiveness and safety profile
Summary
Stroke is a significant cause of death and disability around the world, with a reported 6.5 million deaths, 113 million disability-adjusted life-years lost, and 10.3 million new cases of stroke globally as of 2013.1,2 According to the American Heart Association, around 87% of strokes are ischemic strokes, which occurs when a blood vessel carrying blood to the brain is blocked by a blood clot, with hypertension being the leading risk factor.[3]. Current acute stroke interventions to reduce disability only reach a fraction of patients. In the United States, the only drug approved to treat an acute stroke is through an IV injection of tissue plasminogen activator (tPA),[4,5] which is limited in its effectiveness and safety profile. Only *5% poststroke patients in the United States received tPA acutely.[6,7].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call